Thermo Fisher Scientific is accepting submissions for the fifth round of the Oncomine Clinical Research Grant program.
The program supports clinical and translational research that advances the use of genomic testing to unlock the promise of precision medicine for more cancer patients.
The program awards independent clinical research teams with financial support worth up to $200,000 in reagents and general funding. Since its introduction in 2020, the Oncomine Clinical Research Grant program has provided support to more than 20 research projects across 11 countries in areas including hematology-oncology, immuno-oncology, liquid biopsy, and gene fusion detection.
Grant applications are open through Sept. 26, 2022. For more information on the Oncomine Clinical Research Grant Program and how to submit proposals, click here.
Following the last call for proposals in the spring, the following researchers and projects have been selected as the latest grant recipients:
- Matias Avila, University of Navarra, Pamplona, Spain: “Mutational Analysis of Bile cfDNA for the Early Diagnosis of Biliopancreatic Tumors”
- Wendy Erber, The University of Western Australia, Crawley, Australia: “Genomic Profiling and Disease Monitoring Using Plasma Cell-Free DNA in Acute Myeloid Leukemia”
- Xiuning Le, Anderson Cancer Center: “ctDNA Analysis to Understand Resistance and Response to Osimertinib Ramucirumab Combination Therapy in EGFR Mutant Non-Small Cell Lung Cancer”
- Nir Peled, Shaare Zedek Medical Center, Jerusalem, Israel: “Liquid Biopsy in Suspected Lung Cancer Solitary Pulmonary Nodules”
